Forte Biosciences, Inc. to Announce Third Quarter 2020 Results on November 9
Forte Biosciences, Inc. (NASDAQ: FBRX) will announce its third quarter 2020 results after market close on November 9, 2020, followed by a conference call at 4:30 PM ET. The call will discuss the results and provide a business update. Forte is developing FB-401, a treatment for inflammatory skin diseases, currently in a multi-center clinical trial that includes pediatric, adolescent, and adult subjects aged 2 and older. The trial addresses a significant unmet need for effective therapies in pediatric atopic dermatitis.
- FB-401 is in Phase 1/2a testing for atopic dermatitis, which is a promising step towards effective treatments for inflammatory skin diseases.
- Initiated a multi-center, placebo-controlled clinical trial for FB-401 targeting patients aged 2 and older.
- None.
TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced that it will release third quarter 2020 results after the market close on November 9, 2020 and will host a conference call at 4:30 pm ET to discuss third quarter 2020 results and to provide a general business update.
Conference Call and Webcast Information
Forte management will host a conference call and webcast on November 9, 2020 at 4:30 PM Eastern Time. Participants may access the call by dialing 877-705-6003 (Domestic) or 201-493-6725 (International), the conference ID number is: 13712591. The call will also be webcast and can be accessed from the investor relations section of Forte’s website at https://www.fortebiorx.com/ or http://public.viavid.com/index.php?id=142246. A replay of the call will also be available through November 16th.
About Forte
Forte Biosciences, Inc. is a clinical stage, dermatology company developing a live biotherapeutic, FB-401, for the treatment of inflammatory skin diseases. FB-401 has completed Phase 1/2a testing in adult and pediatric (3 years of age and older) patients with atopic dermatitis. There is a significant unmet need for safe and effective therapies particularly for pediatric atopic dermatitis patients. In September 2020, Forte initiated a multi-center, placebo controlled clinical trial of FB-401 which is expected to enroll pediatric, adolescent and adult AD subjects aged 2 years of age and older. For additional information about the trial, see ClinicalTrials.gov using the identifier NCT04504279.
Source: Forte Biosciences, Inc.
